Small Cell Lung Cancer (SCLC) Market Report and Forecast 2024-2032

Small Cell Lung Cancer (SCLC) Market Outlook:

The small cell lung cancer (SCLC) market size in the 7 major markets is anticipated to grow at a CAGR of 8.3% during the forecast period of 2024-2032. The growth of the market can be attributed to the rising prevalence of small cell lung cancer (SCLC) across these markets.

Small Cell Lung Cancer (SCLC): Introduction

Small cell lung cancer is a rare and lethal lung cancer that grows aggressively. It can affect anyone, but people with a long history of smoking tobacco are most susceptible to SCLC. It can be treated with a high chance of living a healthy life if the disease is detected in the early stages. The only way one can prevent small cell lung cancer is by not smoking.

Small Cell Lung Cancer (SCLC) Market Analysis

The small cell lung cancer (SCLC) market demand is witnessing significant growth due to the increased prevalence of small cell lung cancer (SCLC) among people. The continuous comprehension by the FDA in closing a crucial gap of unmet needs is a major factor expected to be responsible for the growth of the market in the forecast period. For example, the US Food and Drug Administration (FDA) granted orphan drug designation (ODD) to REQORSA(R) immunogene therapy for the combination of its immunogene therapy REQORSA(R). It is therapy that has been developed by a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes. Such designations by the FDA are expected to result in innovation among biotech companies dedicated to developing treatments for people suffering from this disease, further bolstering the small cell lung cancer (SCLC) market growth.

Additionally, to find an appropriate treatment for this life-threatening disease, scientists are continuously engaged in research to discover therapeutics that could act effectively in the treatment or prevention of SCLC. Pharmaceutical companies are participating equally in these research activities. For example, Chugai Pharmaceutical Co., Ltd., Japan's pioneering research-based pharmaceutical company with strengths in biotechnology products, recently declared that their phase III BEAT-SC study, evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) and platinum-based chemotherapy as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), met its primary endpoint of progression-free survival (P89uuFS).

Positive results from such studies stand fair chances to play a crucial role in the development of new therapeutics for effective treatment of SCLC provide better patient outcomes, and act as a catalyst in the demand for such treatments, propelling the market growth in the forecast period.

Small Cell Lung Cancer (SCLC) Market Segmentations

Market Breakup by Diagnosis

• Imaging Tests

• Pulmonary Function Test

• Lung Tissue Analysis 

• Others

Market Breakup by Treatment

• Chemotherapy

• Immunotherapy

• Targeted Therapy 

• Radiation Therapy

• Others

Market Breakup by Route of Administration

• Oral

• Intravenous

• Others

Market Breakup by Gender

• Male

• Female

Market Breakup by End User

• Hospitals

• Homecare

• Specialty Centres

• Others

Market Breakup by Distribution Channel

• Hospital Pharmacy

• Online Pharmacy

• Retail Pharmacy

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

Small Cell Lung Cancer (SCLC) Market Overview

The market growth is driven by the increasing prevalence of small cell lung cancer (SCLC). The rising number of smokers across the world and especially these 7 regions are the major reasons for the increased prevalence of this condition. Lung cancer is the second most diagnosed cancer worldwide. The market growth is further driven by ongoing research and innovations to bring new treatments for cures and diagnostics to enable early detection of this deadly disease. Such innovations and advancements are expected to exhibit an upward trajectory for the forecast cast and contribute to the small cell lung cancer (SCLC) market share. The increasing initiatives to spread awareness about the lethal nature of tobacco smoking are propelling the market further.

Geographically, the United States is dominating the market due to the increased prevalence of the condition. It is estimated that approximately 14% of people who are diagnosed with lung cancer in the United States have SCLC. The market growth is further driven by the increased adaptation of advanced technologies and the availability of healthcare professionals who are aware of SCLC and its symptoms due to which early detection is possible in patients.

Small Cell Lung Cancer (SCLC) Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Teva Pharmaceutical Industries Ltd.

• Sanofi

• F. Hoffmann-La Roche Ltd.

• Mylan N.V.

• Pfizer Inc.

• GSK plc

• Novartis AG

• Bayer AG

• Sun Pharmaceutical Industries Ltd.

• Aurobindo Pharma

• Lupin

• Merck & Co. Inc.

• CLOVIS Oncology

• Johnson & Johnson Private Limited

• Lilly

Please note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report